| Literature DB >> 34071189 |
Justyna Pordzik1, Ceren Eyileten-Postuła1, Daniel Jakubik1, Pamela Czajka1, Anna Nowak1, Salvatore De Rosa2, Aleksandra Gąsecka3, Agnieszka Cieślicka-Kapłon3, Piotr Sulikowski4, Krzysztof J Filipiak3, Dagmara Mirowska-Guzel1, Jolanta M Siller-Matula1,5, Marek Postuła1.
Abstract
MicroRNAs are endogenous non-coding RNAs that are involved in numerous biological processes through regulation of gene expression. The aim of our study was to determine the ability of several miRNAs to predict mortality and response to antiplatelet treatment among T2DM patients. Two hundred fifty-two patients with diabetes were enrolled in the study. Among the patients included, 26 (10.3%) patients died within a median observation time of 5.9 years. The patients were receiving either acetylsalicylic acid (ASA) 75 mg (65%), ASA 150 mg (15%) or clopidogrel (19%). Plasma miR-126, miR-223, miR-125a-3p and Let-7e expressions were assessed by quantitative real time PCR and compared between the patients who survived and those who died. Adjusted Cox-regression analysis was used for prediction of mortality. Differential miRNA expression due to different antiplatelet treatment was analyzed. After including all miRNAs into one multivariate Cox regression model, only miR-126 was predictive of future occurrence of long-term all-cause death (HR = 5.82, 95% CI: 1.3-24.9; p = 0.024). Furthermore, miR-126, Let-7e and miR-223 expressions in the clopidogrel group were significantly higher than in the ASA group (p = 0.014; p = 0.013; p = 0.028, respectively). To conclude, miR-126 expression is a strong and independent predictor of long-term all-cause mortality among patients with T2DM. Moreover, miR-223, miR-126 and Let-7e present significant interactions with antiplatelet treatment regimens and clinical outcomes.Entities:
Keywords: Let-7e; antiplatelet therapy; cardiovascular disease; diabetes; miR-125a-3p; miR-126; miR-223; microRNA; mortality; platelet reactivity
Year: 2021 PMID: 34071189 DOI: 10.3390/jcm10112371
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241